Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma

Documenti analoghi

• Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma
  di: Nil Albiol, et al.
  Pubblicazione: (2026)
• Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
  di: Patrick Born, et al.
  Pubblicazione: (2025)
• Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
  di: Jean Galtier, et al.
  Pubblicazione: (2025)
• Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells
  di: Gloria Iacoboni, et al.
  Pubblicazione: (2024)
• Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
  di: Maeve A. O'Reilly, et al.
  Pubblicazione: (2024)